Carregando...
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
BACKGROUND: The optimal sequence of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequen...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4144818/ https://ncbi.nlm.nih.gov/pubmed/25053178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22844 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|